Valuation : Outlook Therapeutics, Inc.

Market Cap 157M 135M 127M 116M 218M 15.01B 219M 1.5B 587M 7.57B 589M 577M 25.12B P/E 2026 *
-1.11x
P/E 2027 * -2.72x
Enterprise Value 157M 135M 127M 116M 218M 15.01B 219M 1.5B 587M 7.57B 589M 577M 25.12B EV / Sales 2026 *
191x
EV / Sales 2027 * 3.78x
Free-Float
86.07%
Yield 2026 *
-
Yield 2027 * -
1 day+0.59%
1 week-0.36%
Current month-33.96%
1 month-37.99%
3 months-11.66%
6 months+52.82%
Current year-59.18%
1 week 0.61
Extreme 0.6115
0.68
1 month 0.59
Extreme 0.59
1.18
Current year 0.16
Extreme 0.1611
1.88
1 year 0.16
Extreme 0.1611
2.54
3 years 0.16
Extreme 0.1611
18
5 years 0.16
Extreme 0.1611
56.6
10 years 0.16
Extreme 0.1611
878.4
Manager TitleAgeSince
Chief Executive Officer 54 2025-06-30
Chief Executive Officer 60 2024-12-02
Chief Tech/Sci/R&D Officer - 2023-01-18
Director TitleAgeSince
Director/Board Member 60 2018-08-01
Director/Board Member 65 2015-12-10
Chairman 41 2025-01-30
Date Insider Type Main position Quantity % Market Cap.
8/14/26 Buy

Chief Financial Officer

202,020 0.0832%
8/14/26 Buy

Chief Executive Officer

303,030 0.1249%
8/12/26
Gms Ventures & Investments
BuyCompany 5,050,504 2.0812%
Change 5-day change 1-year change 3-year change Capi.($)
+0.59%-0.36%-24.24%-87.99% 157M
-0.60%-1.09%+1.82%+18.92% 50.47B
-6.00%-0.75%+447.48%+524.26% 44.56B
-0.24%+0.74%+37.18%+16.57% 43.08B
-1.55%-2.07%+19.83%+73.63% 41.7B
-0.31%-0.83%+19.47%+48.24% 33.21B
-1.79%-3.24%+26.32%+121.63% 16.77B
-0.58%-2.12% - - 16.28B
-0.33%-1.56%+10.99%+26.88% 14.58B
-1.66%-1.25%+78.49%+39.02% 13.92B
Average -1.25%-1.28%+68.59%+86.80% 27.47B
Weighted average by Cap. -1.64%-1.21%+95.95%+126.38%

Financials

2026 *2027 *
Net sales 824K 710K 666K 608K 1.14M 78.75M 1.15M 7.9M 3.08M 39.75M 3.09M 3.03M 132M 41.57M 35.82M 33.59M 30.66M 57.76M 3.97B 57.94M 398M 155M 2.01B 156M 153M 6.65B
Net income -62.6M -53.94M -50.58M -46.17M -86.98M -5.98B -87.25M -600M -234M -3.02B -235M -230M -10.01B -36.77M -31.68M -29.7M -27.12M -51.08M -3.51B -51.25M -352M -138M -1.77B -138M -135M -5.88B
Net Debt - -
Logo Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Employees
17
Date Price Change Volume
26-08-28 $0.6449 +0.59% 9,494,972
26-08-27 $0.6411 +2.86% 6,853,300
26-08-26 $0.6233 -2.61% 6,063,220
26-08-25 $0.6400 +5.09% 15,948,637
26-08-24 $0.6090 -5.90% 14,797,360
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.6449USD
Average target price
4.900USD
Spread / Average Target
+659.81%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OTLK Stock